Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TeriQ Patch PK and Safety in Healthy Females
NCT06644040Phase 1Completed
- Sponsor
- QuadMedicine
- Start
- Oct 2024
- Primary completion
- Dec 2024
- Modality
- Transdermal Patches, Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of TeriQ in osteoporosis (3 arms), sponsored by QuadMedicine. Primary endpoints: Maximum Plasma Concentration at 8 hours, Time to Maximum Plasma Concentration at 8 hours and 5 more. Started Oct 2024; status: completed.
02
Drugs
TeriQ
03
Conditions
osteoporosis
Beyond the preview
Go deeper on NCT06644040.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06644040.